Antibiotic Prophylaxis in Rhinoplasty
Last updated on July 2021Recruitment
- Recruitment Status
- Enrolling by invitation
- Estimated Enrollment
- 1386
Summary
- Conditions
- Nasal Obstruction
- Nasal Surgical Procedures
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Applicable Clinical TrialMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The study will consist of 2 treatment arms: Treatment arm A: Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg. Treatment arm B: Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 2...
The study will consist of 2 treatment arms: Treatment arm A: Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg. Treatment arm B: Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg every 4 hours or "clindamycin" 150mg every 6 hours, for a duration of three days.
Tracking Information
- NCT #
- NCT04194216
- Collaborators
- Washington University School of Medicine
- Université de Montréal
- Investigators
- Principal Investigator: Sam P Most, MD Stanford Facial Plastic and Reconstructive Surgery
Get Well Soon